Ir directamente a la navegación principal
Ir directamente a la búsqueda
Ir directamente al contenido principal
Clasificar por
Keyphrases
Primary Care
100%
Spain
59%
Catalonia
58%
SIDIAP
35%
Randomized Clinical Trial
33%
Population-based Cohort Study
31%
Non-valvular Atrial Fibrillation
30%
COVID-19
25%
Electronic Health Records
24%
Confidence Interval
23%
Comorbidity
18%
Catalunya
18%
Vitamin K Antagonists
16%
Narcolepsy
16%
Healthcare Electronics
16%
Oral Anticoagulants
16%
Blood Pressure
15%
Moderate to Severe
15%
Placebo
15%
Stroke Prevention
14%
Dabigatran
13%
Odds Ratio
13%
Population-based
13%
Antidepressants
12%
Type 2 Diabetic Patients
12%
Paracetamol
12%
Sweden
12%
Antibiotics
12%
Drug Exposure
12%
Nested Case-control Study
12%
Clinical Trials
11%
Atrial Fibrillation
11%
Non-steroidal Anti-inflammatory Drugs (NSAIDs)
11%
Molluscum Contagiosum
11%
Potassium Hydroxide
11%
Orphan Medicinal Product
11%
Acute Liver Injury
11%
Statin Use
11%
Europe
11%
Electronic Records
11%
Placebo-controlled
11%
Population-based Case-control Study
11%
Exposure during Pregnancy
11%
Gender Differences
11%
Acute Coronary Syndrome
11%
Antibiotic Use
11%
Statins
11%
Secondary Prevention
11%
Drug Use
10%
Denmark
10%
Pharmacology, Toxicology and Pharmaceutical Science
Cohort Study
62%
Atrial Fibrillation
39%
Randomized Clinical Trial
37%
Cerebrovascular Accident
30%
Case-Control Study
29%
Infection
25%
Anticoagulant Agent
24%
Placebo
22%
Clinical Trial
22%
Antibiotics
20%
Diseases
20%
SARS Coronavirus
18%
Cross-Sectional Study
18%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
17%
Antivitamin K
17%
Narcolepsy
16%
Non-Steroidal Anti-Inflammatory Drug
15%
Comorbidity
15%
Adverse Event
15%
Dabigatran
13%
Antidepressant
13%
Paracetamol
13%
Randomized Controlled Trial
12%
Urinary Tract Infection
12%
Pharmacotherapy
12%
Coughing
11%
Analgesic Agent
11%
Cardiovascular Risk
11%
Acute Coronary Syndrome
11%
Antiplatelet
9%
Live Attenuated Influenza Vaccine
9%
Acetylsalicylic Acid
9%
Observational Study
8%
Migraine
8%
Chronic Obstructive Lung Disease
7%
C Reactive Protein
7%
Thromboembolism
7%
Prevalence
7%
Diabetes Mellitus
7%
Pandemic
7%
Peripheral Occlusive Artery Disease
7%
Brain Ischemia
7%
Agomelatine
6%
Influenza A (H1N1)
6%
Cholinergic Receptor Blocking Agent
6%
Bronchitis
6%
Cardiovascular Disease
6%
Apixaban
6%
Maturity Onset Diabetes of the Young
6%
Antihypertensive Agent
6%
Medicine and Dentistry
Primary Health Care
91%
Case-Control Study
33%
Randomized Clinical Trials
31%
COVID-19
24%
Placebo
24%
Atrial Fibrillation
23%
Cohort Analysis
21%
Apoplexy
18%
Infection
17%
Antithrombotic
17%
Electronic Health Record
16%
Severe Acute Respiratory Syndrome Coronavirus 2
15%
Blood Pressure
15%
Cross Sectional Study
14%
Paracetamol
13%
Randomized Controlled Trial
12%
Nonsteroid Antiinflammatory Agent
12%
Coughing
11%
Odds Ratio
11%
Health Care Cost
11%
Narcolepsy
11%
Prevalence
11%
Potassium Hydroxide
11%
Cardiovascular Risk
11%
Molluscum contagiosum
11%
Breast Cancer
11%
Drug Exposure
11%
Communication Skill
11%
Clinical Trial
11%
Diabetes
10%
Vitamin K Antagonist
9%
Drug Therapy
9%
ICD-10
8%
Adverse Event
8%
Diseases
8%
Chronic Obstructive Pulmonary Disease
7%
C Reactive Protein
7%
Thromboembolism
7%
General Practitioner
7%
Diabetes Mellitus
7%
Cohort Study
7%
Acetylsalicylic Acid
7%
Patient with Type 2 Diabetes
7%
Glycon
7%
Dabigatran
6%
Malignant Neoplasm
6%
Clinician
6%
Bronchitis
6%
Parasympatholytic
6%
Apixaban
6%
